Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease)
Abstract
Two Alzheimer's patients with disabling depression failed to respond to standard antidepressants but improved with a monoamine oxidase inhibitor. The author points out that the cholinergic system is involved in Alzheimer's symptoms and that demented patients have high monoamine oxidase levels.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
